Novo Nordisk reports positive results for semaglutide and Victoza at ENDO

3 April 2016

Danish diabetes care giant Novo Nordisk (NOV: N) presented new results from two clinical trials investigating the efficacy and safety of GLP-1 receptor agonists, semaglutide and already blockbuster drug Victoza (liraglutide) for the treatment of type 2 diabetes at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US on April 2.

Semaglutide demonstrated superior improvements in glycemic control vs placebo in adults with type 2 diabetes

The 30-week SUSTAIN 1 trial evaluating the efficacy and safety of semaglutide monotherapy versus placebo in 388 adults with type 2 diabetes, showed that, from a mean baseline HbA_1c of 8.1%, adults treated with 0.5mg and 1.0mg semaglutide achieved significantly greater HbA_1creductions of 1.5% and 1.6%, respectively, vs <0.1% with placebo.

More adults treated with 0.5mg and 1.0mg semaglutide achieved HbA_1c targets compared with placebo: HbA_1c <7% (74% and 72% vs 25%) and ≤6.5% (59% and 60% vs 13%).

Adults treated with 0.5mg and 1.0mg semaglutide achieved significantly greater reductions from baseline in mean body weight of 3.7kg/8.16 lb and 4.5kg/9.92 lb, respectively, vs 1.0kg/2.20 lb with placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK